Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome.

Rueda, Noemí; Flórez, Jesús; Dierssen, Mara; Martínez-Cué, Carmen

Rueda, Noemí; Flórez, Jesús; Dierssen, Mara; Martínez-Cué, Carmen.

Afiliação

Rueda N; Department of Physiology and Pharmacology, University of Cantabria, Santander, Spain.
Flórez J; Department of Physiology and Pharmacology, University of Cantabria, Santander, Spain.
Dierssen M; Cellular and Systems Neurobiology, Systems Biology Program, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology, Universitat Pompeu Fabra (UPF), Barcelona, Spain.
Martínez-Cué C; Department of Physiology and Pharmacology, School of Medicine, University of Cantabria, Santander, Spain. Electronic address: carmen.martinez-cue@unican.es.

Prog Brain Res ; 251: 245-268, 2020.

Article em En | MEDLINE | ID: mdl-32057309

Assuntos

Doença de Alzheimer; Modelos Animais de Doenças; Síndrome de Down; Pesquisa Translacional Biomédica/normas; Doença de Alzheimer/tratamento farmacológico; Doença de Alzheimer/genética; Doença de Alzheimer/metabolismo; Animais; Síndrome de Down/tratamento farmacológico; Síndrome de Down/genética; Síndrome de Down/metabolismo

Palavras-chave

Down syndrome; Induced pluripotent stem cells (iPSCs); Mouse models; Pharmacotherapies; Translational validity

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Down / Modelos Animais de Doenças / Pesquisa Translacional Biomédica / Doença de Alzheimer Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google